News articles about Fluidigm Corporation (NASDAQ:FLDM) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fluidigm Corporation earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 46.2485520545813 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern Sentiment’s analysis:

FLDM has been the topic of several analyst reports. Zacks Investment Research raised shares of Fluidigm Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, June 1st. ValuEngine downgraded shares of Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.

Shares of Fluidigm Corporation (NASDAQ FLDM) opened at 5.25 on Wednesday. The company’s 50-day moving average is $3.90 and its 200 day moving average is $4.62. The stock’s market cap is $154.42 million. Fluidigm Corporation has a 1-year low of $2.52 and a 1-year high of $8.82.

Fluidigm Corporation (NASDAQ:FLDM) last issued its quarterly earnings results on Thursday, August 3rd. The medical research company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.02. Fluidigm Corporation had a negative net margin of 74.05% and a negative return on equity of 121.04%. The firm had revenue of $23.90 million during the quarter, compared to the consensus estimate of $23.50 million. During the same period in the prior year, the firm earned ($0.63) EPS. The business’s revenue was down 15.2% on a year-over-year basis. Equities research analysts anticipate that Fluidigm Corporation will post ($2.13) EPS for the current year.

In related news, insider Steven Mcphail purchased 20,000 shares of Fluidigm Corporation stock in a transaction on Tuesday, August 8th. The stock was purchased at an average cost of $3.00 per share, with a total value of $60,000.00. Following the acquisition, the insider now directly owns 27,842 shares in the company, valued at $83,526. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Levin Capital Strategies, L.P. purchased 4,003,129 shares of Fluidigm Corporation stock in a transaction on Thursday, August 10th. The stock was bought at an average cost of $3.30 per share, with a total value of $13,210,325.70. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 4,106,038 shares of company stock valued at $13,496,083. Insiders own 4.70% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Fluidigm Corporation (FLDM) Earns Media Impact Rating of 0.16” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at

Fluidigm Corporation Company Profile

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Insider Buying and Selling by Quarter for Fluidigm Corporation (NASDAQ:FLDM)

Receive News & Stock Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related stocks with our FREE daily email newsletter.